Regulatory Bayer’s asundexian starts EU review for ischaemic stroke PharmaphorumThe EMA has started its review of Bayer's asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J J.CardiovascularRead full story pharminent June 10, 2026 (Last updated: June 10, 2026) Pharmaphorum The EMA has started its review of Bayer’s asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J J. Cardiovascular Read full story Post navigation Previous: AbbVie’s migraine drug cleared for migraine attacks on NHSNext: Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026